Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Frontiers in OncologyOpen Access

Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaokun LiZCZhuang‐Zhuang CongYQYong Qiang

Discussion

Loading...

Member takes

Overview

Editorial reviews the impact of neoadjuvant therapy on survival rates in esophageal cancer, suggesting tailored treatment options.

Key Points

  • Neoadjuvant therapy improves overall survival in patients with locally advanced esophageal cancer, and it is essential for better outcomes.
  • Results from the CROSS trial show a 13% absolute survival advantage when combining surgery with neoadjuvant chemoradiotherapy.
  • Patients with squamous cell carcinoma show significantly higher pathological complete response rates when treated with neoadjuvant therapy compared to surgery alone.
  • Future research must focus on enhancing treatment regimens and identifying biomarkers for personalized neoadjuvant therapies.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3f31b076d99fa54e89https://doi.org/10.3389/fonc.2025.1688480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma2024 · 1 citations
  2. 2Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study2026 · 2 citations
  3. 3Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials2025 · 2 citations
  4. 4Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review2025
  5. 5474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025